desmoglein

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/11/29 13:52:03」(JST)

wiki en

The desmogleins are a family of cadherins consisting of proteins DSG1, DSG2, DSG3, and DSG4. They play a role in the formation of desmosomes that join cells to one another.

Pathology

Desmogleins are targeted in the autoimmune disease pemphigus.^[1]^[2]^[3]

References

^ Waschke J, Bruggeman P, Baumgartner W, Zillikens D, Drenckhahn D (November 2005). "Pemphigus foliaceus IgG causes dissociation of desmoglein 1–containing junctions without blocking desmoglein 1 transinteraction". J. Clin. Invest. 115 (11): 3157–65. doi:10.1172/JCI23475. PMC 1242188. PMID 16211092.
^ Kljuic A, Bazzi H, Sundberg JP, et al. (April 2003). "Desmoglein 4 in hair follicle differentiation and epidermal adhesion: evidence from inherited hypotrichosis and acquired pemphigus vulgaris". Cell 113 (2): 249–60. doi:10.1016/S0092-8674(03)00273-3. PMID 12705872.
^ Müller R, Heber B, Hashimoto T, et al. (May 2009). "Autoantibodies against desmocollins in European patients with pemphigus". Clin. Exp. Dermatol. 34 (8): 898–903. doi:10.1111/j.1365-2230.2009.03241.x. PMID 19456767.

External links

Histology image: 20502loa - Histology Learning System at Boston University
Desmogleins at the US National Library of Medicine Medical Subject Headings (MeSH)

This protein-related article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 天疱瘡の病因、臨床症状、および診断 pathogenesis clinical manifestations and diagnosis of pemphigus
2. Arrhythmogenic right ventricular cardiomyopathy: Pathogenesis and genetics
3. 難治性の尋常性天疱瘡および落葉状天疱瘡のマネージメント management of refractory pemphigus vulgaris and pemphigus foliaceus
4. 尋常性天疱瘡および落葉状天疱瘡の初期マネージメント initial management of pemphigus vulgaris and pemphigus foliaceus
5. Netherton syndrome

English Journal

Low-dose rituximab is effective in pemphigus.

Horváth B, Huizinga J, Pas HH, Mulder AB, Jonkman MF.SourceDepartments of Dermatology Laboratory Medicine, Centre for Blistering Diseases, University Medical Centre Groningen, University of Groningen, PO Box 30001, 9700 RB Groningen, the Netherlands.
The British journal of dermatology.Br J Dermatol.2012 Feb;166(2):405-12. doi: 10.1111/j.1365-2133.2011.10663.x. Epub 2012 Jan 9.
Background Rituximab, an anti-CD20 antibody, was shown in open series studies to be effective in treating pemphigus at a dose of 4 × 375 mg m(-2) as approved for B-cell malignancies. Objectives We investigated whether a lower dose of rituximab is also effective for pemphigus. Methods
PMID 21967609